幼年特发性关节炎合并巨噬细胞活化综合征的药物治疗进展  

Advances in drug therapy for juvenile idiopathic arthritis combined with macrophage activation syndrome

作　　者：曹璐[1] 许静[1] 张永[1] 景霞[1] 湛雯[1] 徐进[1] 

机构地区：[1]南京医科大学附属儿童医院,江苏南京210008

出　　处：《安徽医药》2017年第4期600-604,共5页Anhui Medical and Pharmaceutical Journal

摘　　要：巨噬细胞活化综合征(MAS)是幼年特发性关节炎(JIA)并发症的一种,严重者可致命。目前,临床上尚无治疗该并发症的应用指南。该文综述了幼年特发性关节炎合并MAS的药物治疗进展,包括传统治疗JIA的药物以及新型生物制剂。旨在临床为该病的治疗提供用药指导。Macrophage activation syndrome （MAS） is a serious fatal complication of rheumatic diseases,which is seen most frequently in systemic juvenile idiopathic arthritis （JIA）. Up to now, there are no clinical application guidelines for the treament of such complica-tion. Here, this paper reviewed the drug of JIA combined with MAS treatment, including the traditional medicines used in JIA and the new biological agents,which aimed to provide guidance of rational drug use for clinics.

关 键 词：幼年特发性关节炎 巨噬细胞活化综合征 传统药物 新型生物制剂 

分 类 号：R725.9[医药卫生—儿科]